<DOC>
	<DOCNO>NCT02342444</DOCNO>
	<brief_summary>The risk develop blood clot occur 60 % critical care patient . Many time enoxaparin ( Lovenox ) give patient higher risk develop clot legs lung . There two standard dos enoxaparin recommend drug company . These two dos never directly compare trauma , general , vascular surgery patient . The purpose study : 1. compare development blood clot patient receive 30mg twice daily enoxaparin compare patient receive 40mg daily enoxaparin . 2. determine high risk bleed complication patient receive 30mg twice daily enoxaparin compare patient receive 40mg daily . Patients enrol study randomize receive enoxaparin , 30mg twice daily enoxaparin , 40mg daily . Patients monitor sign symptom blood clot . At time discharge ( , medically indicate ) , ultrasound test perform look blood clot patient 's leg . The investigator compare incidence blood clot form 2 group patient determine one dose enoxaparin relate low rate blood clot critically ill patient . The investigator also compare incidence bleeding complication 2 group .</brief_summary>
	<brief_title>Lovenox 30 mg Twice Daily ( BID ) Versus 40 mg Once Daily ( QD )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Admitted patient require prophylactic dosing enoxaparin ( Lovenox ) Admitted trauma surgical service Age great 15 year Unable obtain consent patient authorize representative Presence intracranial hemorrhage Receiving therapeutic dose enoxaparin ( Lovenox ) Receiving form anticoagulation Presence renal failure require nonstandard dose regimen</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Trauma</keyword>
	<keyword>Surgery</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>DVTs</keyword>
	<keyword>Thromboembolic event</keyword>
</DOC>